CN101146767A - Taurine synthesis, production and utility as a medicine - Google Patents

Taurine synthesis, production and utility as a medicine Download PDF

Info

Publication number
CN101146767A
CN101146767A CNA2005800460663A CN200580046066A CN101146767A CN 101146767 A CN101146767 A CN 101146767A CN A2005800460663 A CNA2005800460663 A CN A2005800460663A CN 200580046066 A CN200580046066 A CN 200580046066A CN 101146767 A CN101146767 A CN 101146767A
Authority
CN
China
Prior art keywords
effective
concentration
prevention
compositions
taurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800460663A
Other languages
Chinese (zh)
Inventor
M·A·K·阿布达拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN101146767A publication Critical patent/CN101146767A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The quantitatively most important pathway for the excretion of cholesterol in mammals is the formation of bile salts (the conjugate bases of bile acids). The major bile salts are synthesized and secreted by as glycine or taurine conjugates. Taurine (2 aminoethyl sulphonic acid) is naturally produced by the liver cells and central nervous system cells, it is neuroprotective and is a cholesterol lowering agent with virtually no recorded side effects.

Description

Synthetic, the preparation of taurine and as the purposes of medicine
Technical field
1. medicine
Background technology
In the Mammals with regard to quantity the approach of most important excretion of cholesterol for forming biliary salts (conjugate base of bile acide).Most biliary saltss are synthetic and secretion with the form of the binding substances of glycine or taurine.
Summary of the invention
Taurine is a kind of degraded product of halfcystine.Taurine (2-aminoethyl sulfonic acid) is biliary a kind of component.Taurine combines with cholic acid and forms taurocholate.Cholic acid is the meta-bolites of cholesterol.The formation of cholic acid comprises a kind of approach that relates to several hydroxylatings and oxidizing reaction.All water-soluble vitaminss all participate in these reactions.
But the taurine reducing cholesterol, and this effect is strengthened by the existence of water-soluble vitamins.
Taurine can effectively reduce hypercholesterolemia (hypercholesterolaemia), hypertriglyceridemia (hypertriglyceridaemia) and all lipid disorders, as cholestasis or nephrotic syndrome etc.Taurine is also to various types of familials or congenital or the acquired character lipid disorders is effective.Taurine has cardioprotection (cardioprotective).
Taurine also to the cholelith dissolving effectively.
Taurine can securely and effectively make hypercholesterolemia, low-density lipoprotein or vldl normalizing.
Taurine is also aspect the change of stablizing brain cell antagonism colloidal osmotic pressure, and essential to the conversion aspect of endorphin by thrombotonin.It is also effective to depression, migraine, headache, alzheimer's disease and psychosis and sacred disease.
Neodoxy:
In order to control lipid in the blood, lipoprotein, cholesterol level, to control disease, psychosis and the sacred disease relevant, and be used for the cholelith dissolving with the hypercholesterolemia blood level, following material uses separately or is used in combination is effective:
A. taurine
B. halfcystine and/or acetylcysteine,
C. all water-soluble vitaminss.
Embodiment
A. taurine prepares by all known modes, as: earlier ethanol is carried out sulfonation and on C2, carry out substitution reaction then, or, prepare 2 taurines by recombinant DNA technology or any possible mode; Perhaps by using probiotic bacterium (probiotics) promoting the utilization of intestinal bacterium fauna, with the taurine of regenerating the taurocholate that forms from previous liver and the Taurochenodeoxycholic Acid, etc..
B. acetylcysteine is by all known way preparations.
C. water-soluble vitamins is by all known way preparations.
Wherein:
I. as if the form administration with " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c ", all " a ", " b " and " c " are effective.
Ii. if with oral or parenteral or the topical preparation's mode form administration with " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c ", all " a ", " b " and " c " are effective.
Iii. all of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any composition and any and all concentration are all effective.
Iv. used taurine occurs with the form of its acid or hydrochlorate or alkali salt or with its any compound or form.
V. any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions are in prevention with asthersclerosis is controlled in control and cardiac disease is all effective.
Vi. any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions have hypercholesterolemia, hypertriglyceridemia and all and any lipid and lipoprotein all effective aspect disorderly in prevention and control seat of local government.
Vii. any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions are controlled aspect the cholestasis of any cause of disease all effective in prevention and control.
Viii. any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions are controlled aspect the fatty degeneration of liver of any cause of disease and the fat hepatitis all effective in prevention and control.
Ix. any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions are controlled aspect the chololithiasis all effective in prevention, dissolving and control.
X. any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions are all effective aspect prevention and control seat of local government spiritedness disease and all sacred diseases.

Claims (10)

1.a. taurine prepares by all known modes, as: earlier ethanol is carried out sulfonation and on C2, carry out substitution reaction then, or, prepare 2 taurines by recombinant DNA technology or any possible mode; Perhaps by using probiotic bacterium promoting the utilization of intestinal bacterium fauna, with the taurine of regenerating the taurocholate that forms from previous liver and the Taurochenodeoxycholic Acid, etc..
B. acetylcysteine is by all known way preparations;
C. water-soluble vitamins is prepared by all known ways,
Wherein:
1. as if the form administration with " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c ", all " a ", " b " and " c " are effective;
2. if with oral or parenteral or the topical preparation's mode form administration with " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c ", all " a ", " b " and " c " are effective;
3. all of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any composition and any and all concentration are all effective;
4. used taurine occurs with the form of its acid or hydrochlorate or alkali salt or with its any compound, form or shape;
5. any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions are in prevention with asthersclerosis is controlled in control and cardiac disease is all effective;
6. it is all effective aspect disorderly that any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions have hypercholesterolemia, hypertriglyceridemia and all any lipids and lipoprotein in prevention and control seat of local government;
7. any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions are controlled aspect the cholestasis of any cause of disease all effective in prevention and control;
8. any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions are controlled aspect the fatty degeneration of liver of any cause of disease and the fat hepatitis all effective in prevention and control;
9. any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions are controlled aspect the chololithiasis all effective in prevention and control;
10. any and all concentration of " a " or " b " or " c " or " a+b " or " a+c " or " b+c " or " a+b+c " form and any and all compositions are all effective aspect prevention and control seat of local government spiritedness disease and all sacred diseases.
CNA2005800460663A 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine Pending CN101146767A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2005010013 2005-01-05
EG2005010013 2005-01-05

Publications (1)

Publication Number Publication Date
CN101146767A true CN101146767A (en) 2008-03-19

Family

ID=36647837

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800460663A Pending CN101146767A (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine

Country Status (15)

Country Link
EP (1) EP1844006A2 (en)
JP (1) JP2008526789A (en)
KR (1) KR20070091198A (en)
CN (1) CN101146767A (en)
AP (1) AP2007004084A0 (en)
AU (1) AU2005324199A1 (en)
BR (1) BRPI0519606A2 (en)
CA (1) CA2593563A1 (en)
EA (1) EA200701434A1 (en)
IL (1) IL184221A0 (en)
MA (1) MA29238B1 (en)
MX (1) MX2007008196A (en)
NO (1) NO20074937A (en)
TN (1) TNSN07226A1 (en)
WO (1) WO2006072259A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106728405A (en) * 2016-11-15 2017-05-31 陈思文 A kind of taurine and water soluble tea polyphenol compound and preparation method and application

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2214480T3 (en) 2007-11-30 2013-11-29 Univ California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
CN103382170B (en) * 2012-10-25 2015-04-08 潜江永安药业股份有限公司 Preparation method for taurine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58140017A (en) * 1981-12-22 1983-08-19 Junichi Azuma Remedy for cardiac insufficiency
JPH08208464A (en) * 1994-12-02 1996-08-13 Taisho Pharmaceut Co Ltd Agent for treatment and prevention of hyperlipemia
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
SE9601395D0 (en) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
WO2001026642A2 (en) * 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CN1340502A (en) * 2000-06-30 2002-03-20 张永春 Process for preparing taurine zinc
CN1268733C (en) * 2004-07-20 2006-08-09 刘辉 Taurine functional beer and its producing process

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106728405A (en) * 2016-11-15 2017-05-31 陈思文 A kind of taurine and water soluble tea polyphenol compound and preparation method and application

Also Published As

Publication number Publication date
WO2006072259A3 (en) 2007-10-04
KR20070091198A (en) 2007-09-07
EP1844006A2 (en) 2007-10-17
EA200701434A1 (en) 2008-10-30
NO20074937A (en) 2007-09-28
WO2006072259A2 (en) 2006-07-13
TNSN07226A1 (en) 2008-11-21
AU2005324199A1 (en) 2006-07-13
MX2007008196A (en) 2008-02-22
AP2007004084A0 (en) 2007-08-31
BRPI0519606A2 (en) 2009-02-25
IL184221A0 (en) 2008-12-29
JP2008526789A (en) 2008-07-24
MA29238B1 (en) 2008-02-01
CA2593563A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
DE69628290T2 (en) METHODS AND COMPOSITIONS FOR LIPIDIZING HYDROPHILIC MOLECULES
TW589186B (en) Ascorbyl-phosphoryl-cholesterol
CN102438978B (en) polyamine derivatives
TW570805B (en) Water-soluble pharmaceutical composition in an ionic complex
DE10207178A1 (en) Components for the production of amphoteric liposomes
US20190351068A1 (en) Compositions and methods for drug delivery
JP2005298505A (en) Method for promoting percutaneous absorption of pheum palmatum extract using high-pressure emulsification technology and whitening skin lotion composition prepared by using the same
WO1997030170A1 (en) Composition for the transfection of higher eucaryotic cells
TW200836716A (en) Use of substituted pyranone acid derivatives for producing medicaments for treating the metabolic syndrome
CN101146767A (en) Taurine synthesis, production and utility as a medicine
WO2014203885A1 (en) Collagen production promoter
CN102686213B (en) Pigmentation-preventing or -ameliorating agent
JP5685315B2 (en) Pharmaceutical or cosmetic composition comprising nicotinic acid adenine dinucleotide phosphate or a derivative thereof
EP2600856B1 (en) Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer
WO2007078848A3 (en) Preparation of pharmaceutical salts of 3-o-(3&#39;,3&#39;-dimethlsuccinyl) betulinic acid
WO2010056145A1 (en) Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations
ITMI20121749A1 (en) HELIANTHUS ANNUUS EXTRACTS USEFUL IN THE TREATMENT OF THE METABOLIC SYNDROME AND IN THE DECREASE OF THE GLICEMIC FOOD INDEX AND PROCEDURE FOR THEIR PREPARATION AND THE COMPOSITIONS THAT CONTAIN THEM
DE19814815C2 (en) Sterin-linked, anionic cyclodextrin derivatives and their use in pharmaceutical formulations
JP2017137269A (en) Promoter for expression of hyaluronan synthase gene
DE19952957B4 (en) Modular transport systems for molecular substances and their preparation and use
CN103772469A (en) Synthetic cation lipid with zoosterol and natural arginine structural fragment and synthesis method and application thereof
JP5033388B2 (en) Composition
US10828312B2 (en) Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer&#39;s disease and neurological disorders
Tena-Solsona et al. Self-assembled multivalent (SAMul) ligand systems with enhanced stability in the presence of human serum
CN118453657B (en) Stem cell therapy method for graft versus host disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20080319